Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. develops clinical-stage immune-oncology therapeutics for cancer using its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies. News about APVO centers on mipletamig, its CD123 x CD3 program for acute myeloid leukemia, including clinical data, safety observations, orphan drug designation for AML, and combination studies with venetoclax and azacitidine.
Company updates also cover pipeline expansion into bispecific, multispecific and trispecific candidates, solid-tumor work such as ALG.APV-527, conference presentations, financing arrangements, operating results, shareholder voting matters, and governance changes tied to Aptevo’s public-company structure.
Aptevo Therapeutics (NASDAQ:APVO) reported a Q1 2026 business update highlighting mipletamig data in frontline AML, leadership changes, and new financing.
Mipletamig showed an 87% clinical benefit rate, 81% CR/CRi, 65% CR, 52% MRD-negative among CR/CRi, and no CRS in frontline patients across 31 evaluable patients.
The RAINIER trial remains on track for completion and Phase 2 dose selection by year end. Jeff Lamothe became CEO, Marvin White Executive Chair. Aptevo held $14.5 million in cash on March 31, 2026, and secured a new $60 million SEPA extending capital access into 2029.
Aptevo (Nasdaq:APVO) reported topline RAINIER frontline AML data through Cohort 5 showing 87% clinical benefit and 81% remission (CR/CRi) in 31 evaluable patients treated with mipletamig plus venetoclax and azacitidine. Cohorts 6–7 and two six-patient groups will complete the dataset for RP2D selection, with trial completion and Phase 2 dose selection on track for 2026.
Key numeric outcomes: 65% CR rate, 55% MRD-negativity among CR/CRi, 36% of remissions in TP53-mutant patients, six patients proceeded to allogeneic transplant, and no cytokine release syndrome reported.
Aptevo Therapeutics (Nasdaq:APVO) reported 2025 financial results and a business update on March 26, 2026. Clinical data for mipletamig showed an 86% clinical benefit rate in 28 frontline AML patients and no cytokine release syndrome observed to date. The company expanded its CD3 multispecific portfolio and established a $60 million equity line; year-end cash was $21.6 million, with resources expected to fund operations into Q4 2026.
Aptevo Therapeutics (NASDAQ:APVO) will participate in two March 2026 conferences: the 38th Annual Roth Conference (Dana Point, CA) and BIO-Europe Spring (Lisbon, Portugal).
Aptevo incoming CEO Jeff Lamothe will join a company fireside chat on March 23, 2026 at 1:30 PM PT. Michelle H. Nelson, PhD, will present Aptevo's trispecific ADAPTIR-FLEX molecules on March 24, 2026 at 1:15 PM ET. Events include investor meetings, panels, and partnering opportunities.
Aptevo Therapeutics (NASDAQ:APVO) reported interim frontline AML data for mipletamig combined with venetoclax and azacitidine showing an 86% clinical benefit rate (CR/CRi/PR) among 28 evaluable patients and 0% cytokine release syndrome (CRS).
Key metrics: 79% CR/CRi, 61% CR, 55% of CR/CRi patients reached MRD-negative status, 35% of remissions had TP53 mutation, and four patients proceeded to allogeneic stem cell transplant. Data are interim and enrollment continues in the RAINIER program.
Aptevo (Nasdaq: APVO) announced executive leadership transitions effective April 1, 2026: Marvin White will move from President & CEO to Executive Chair and Jeff Lamothe will become President & CEO and join the Board; John E. Niederhuber, M.D., will become Lead Independent Director.
The company highlighted clinical progress (more than 100 patients treated with mipletamig), an expanded eight-molecule pipeline including trispecific programs, a partnership with Alligator Bioscience, and a financial runway into 2029 including a $60 million equity line.
Aptevo Therapeutics (NASDAQ: APVO) entered a $60 million equity line of credit with Yorkville Advisors to provide incremental, market-based capital access. Combined with cash on hand, the fully leveraged facility is stated to extend Aptevo's funding runway into 2029 to support clinical and preclinical multispecific oncology programs. Proceeds will fund ongoing clinical development, advance preclinical programs, and general corporate purposes. The company retains discretion to draw on the facility; terms note minimal fees and no warrants. Aptevo's pipeline includes five CD3-engaging assets led by mipletamig (CD123×CD3), evaluated in >100 patients with reported high remission rates and no observed cytokine release syndrome in frontline patients to date.
Aptevo Therapeutics (NASDAQ:APVO) will implement a 1-for-18 reverse stock split, effective December 29, 2025 at 5:01 p.m. ET, with split-adjusted trading expected to begin on Nasdaq at market open on December 30, 2025.
Every 18 pre-split shares will convert into one post-split share, reducing outstanding common stock from approximately 18 million to approximately 1 million (subject to rounding and issuances). The company will not change its trading symbol APVO. Outstanding options, RSUs, warrants and equity-plan share counts will be adjusted; fractional shares will be cashed out. The split was approved by stockholders July 24, 2025 and the board set the final ratio on December 17, 2025.
Aptevo Therapeutics (NASDAQ:APVO) presented preliminary Phase 1b/2 RAINIER data for mipletamig (CD123 x CD3) combined with azacitidine and venetoclax for newly diagnosed AML patients unfit for intensive chemotherapy at ASH on December 8, 2025.
Key readouts: 100% of patients in Cohorts 1–3 remained free of cytokine release syndrome (CRS); 93% ORR among evaluable patients; 87% CR/CRi; 73% CR; 60% of MRD-evaluable CR/CRi patients were MRD negative; 43% of ORR patients had TP53 mutations. Median age was 75. The triplet was generally well tolerated; infusion-related reactions and hematologic events were the most common adverse events. The trial is continuing enrollment across additional dose levels.
Aptevo (NASDAQ:APVO) presented first preclinical data for its trispecific antibody candidate APVO451 at the Society for Immunotherapy of Cancer Annual Meeting on November 8, 2025. APVO451 targets nectin-4 to localize activity, uses a CRIS-7-derived CD3 binding domain to activate T cells without observed cytokine release syndrome in related programs, and engages CD40 to restore antigen-presenting cell function.
Key preclinical findings showed tumor-localized T‑cell and APC activation, superior elimination of nectin-4+ tumor cells versus a standard CD3 engager in suppressive tumor models, and ongoing IND‑enabling preclinical studies.